Princess Margaret Cancer Centre
Medical Oncology Department
Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université
Claude Bernard for her research on the independents factors that determine medical practices in oncology. She also received
Master’s degrees in in statistics in 1995 and in medical economy in 1996. From 2008 to 2013, she has served as Chairman of the
gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of
the national network dedicated to diagnosis and management of the rare gynecological cancer (www.ovaire-rare.org), a network
funded by the INCA commission. At the Groupe d’investigateurs national evaluation des cancers de l’ovaire (GINECO), she has
been active in the translational research advisory committee, the scientific committee, and as a chairman of endometrial cancer
subgroup and the rare tumors committee. Since 2002, she is also developing translational research dedicated to ovarian cancer
with the INSERM within the CRCL directed by A Puisieux within the CLB campus, and more directly with the research on rare gyn
cancer biology (Carcinosarcoma, Granulosa cell tumors..). From 2009 to 2018, she was the chairman of the rare cancer working
group from GCIG (gynaecological cancer intergroup) dedicated to clinical trials in the field of all rare gynaecological cancers. She
is the current President of the GINECO group. She is an active member of a number of professional groups, including the American
Society of Clinical Oncology, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of
Cancer Research, the EORTC organisation and the European Society of Medical Oncology (ESMO) and the European Society of
Gynaecological Oncology (ESGO).
Moderator of 2 Sessions
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Chair(s)
Session Description
This session is dedicated to innovations in ovarian cancer biology, surgery and treatment. Speakers in this session will cover the role of “biology” in clinical outcomes and potential for surgical decision making, timing and new approaches. With the growing interest in intraoperative treatments, a critical appraisal of HIPEC will be performed. The second part will discuss current and emerging systemic therapies in the first-line setting and how the ongoing trials may change clinical practice. Next, several “hot topics” in ovarian cancer will be presented, including the mechanisms of resistance to PARP inhibitors, front-line maintenance therapy as part of standard-of-care (SOC) for at least 50% of women with ovarian cancer and the new and very promising developmental therapies. To close this session dedicated to ovarian cancer, a debate on the role of surgery for relapsed disease from the US and European perspectives will be debated.
Session Type
Poster Rounds & Sponsor Conversation Break
Date
10/01/2022
Session Time
12:05 PM - 12:35 PM
Room
Sponsor Conversation Area
Chair(s)
Session Description
Poster Rounds Groups O1, O2 & O3. For the full schedule, please click on the Poster Rounds green button on top of the interactive program or visit the IGCS 2022 Mobile App.
Presenter of 6 Presentations
Panel Discussion
Session Type
Plenary Session
Date
09/30/2022
Session Time
02:45 PM - 03:55 PM
Room
Hall 501
Presenter
- Robert L Coleman (United States of America)
- Paul A. DiSilvestro (United States of America)
- Antonio Gonzalez-Martin (Spain)
- Thomas J. Herzog (United States of America)
- Mansoor R. Mirza (Denmark)
- Bradley J. Monk (United States of America)
- Kathleen N. Moore (United States of America)
- Amit Oza (Canada)
- Isabelle L. Ray-Coquard (France)
- Brian M. Slomovitz (United States of America)
- Jonathan A. Ledermann (United Kingdom)
Lecture Time
03:13 PM - 03:51 PM
Group Discussion: Impact of PARP Inhibitors on subsequent therapies
Session Name
Session Type
Industry Symposia
Date
09/29/2022
Session Time
11:55 AM - 01:25 PM
Room
Hall 405
Presenter
Lecture Time
01:00 PM - 01:25 PM
• Potential impact on standard of care: Review of pending trials - Overview
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Presenter
Lecture Time
04:30 PM - 04:42 PM
How to define PARP Resistance
Session Name
Session Type
Industry Symposia
Date
09/29/2022
Session Time
11:55 AM - 01:25 PM
Room
Hall 405
Presenter
Lecture Time
12:15 PM - 12:30 PM
PANEL 2: DEVELOPMENTAL THERAPEUTICS (25 min) – moderated by Isabelle Ray-Coquard
Session Name
Session Type
Master Session
Date
09/30/2022
Session Time
04:00 PM - 06:25 PM
Room
Hall 501
Presenter
Lecture Time
04:54 PM - 04:54 PM
SEMINAL ABSTRACT PRESENTATION: FINAL OVERALL SURVIVAL (OS) RESULTS FROM THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL EVALUATING MAINTENANCE OLAPARIB (OLA) PLUS BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC)
Session Type
Plenary Session
Date
09/30/2022
Session Time
02:45 PM - 03:55 PM
Room
Hall 501
Presenter
Lecture Time
02:53 PM - 02:58 PM
Abstract
Objectives
In the PAOLA-1/ENGOT-ov25 (NCT02477644) primary analysis, adding ola to maintenance bev after first-line (1L) platinum-based chemotherapy (PBC) + bev led to a significant progression-free survival (PFS) benefit in AOC (HR 0.59, 95% CI 0.49–0.72; P<0.001), particularly in pts with homologous recombination deficiency (HRD+; BRCA1/2 mutation [BRCAm] and/or genomic instability; Ray-Coquard et al NEJM 2019). Here, we report the prespecified final OS analysis.Methods
Pts with high-grade AOC, in response after PBC + bev, were randomized 2:1 to ola tablets (300 mg bid; up to 24 months [mo]) + bev (15 mg/kg q3w; 15 mo total) or placebo [pbo] + bev. OS (intent-to-treat [ITT] population) was a key secondary endpoint, with analysis planned for 3 years after the primary analysis as part of hierarchical testing.Results
537 pts were randomized to ola + bev and 269 to pbo + bev (median follow-up 61.7 and 61.9 mo, respectively; OS data maturity: 55.3%). Median OS in the ITT population was 56.5 mo with ola + bev vs 51.6 mo with pbo + bev (HR 0.92, 95% CI 0.76–1.12; P=0.4118; OS at 5 y, 47.3 vs 41.5%). In HRD+ pts, OS was prolonged with ola + bev (HR 0.62, 95% CI 0.45–0.85; OS at 5 y, 65.5 vs 48.4%), with benefit in HRD+ pts with or without a tumour BRCAm (tBRCAm; Table). No benefit was seen in HRD- pts (HR 1.19, 95% CI 0.88–1.63). Subsequent PARP inhibitor therapy was received by 105 (19.6%) ola + bev pts vs 123 (45.7%) pbo + bev pts. Myelodysplastic syndrome, acute myeloid leukaemia and aplastic anaemia incidence, and new primary malignancy incidence, was respectively: ola + bev, 9 pts [1.6%] and 22 pts [4.1%]; pbo + bev, 6 pts [2.2%]) and 8 pts [2.9%]).Conclusions
Despite a high proportion of pts in the control arm receiving a PARP inhibitor post-progression, ola + bev provided a clinically meaningful improvement in OS for 1L HRD+ pts with and without a tBRCAm, confirming ola + bev as standard of care in this setting.Funding: ARCAGY Research, AstraZeneca, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and F. Hoffmann-La Roche.
Permission statement: Previously presented at the European Society for Medical Oncology (ESMO) 2022, FPN (Final Publication Number): LBA29, Isabelle Ray-Coquard et al. Reused with permission.